The discovery of lead compounds for classical druggable targets has become increasingly efficient; however, the development of therapeutics targeting “undruggable” targets continues to face significant hurdles and unmet needs. One of the key challenges in the hit-finding stage is the difficulty in identifying initial hits and obtaining seed compounds that can serve as viable starting points for lead optimization.